Wyeth PFE

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New Morningstar Analyst Report for Teva Pharmaceutical Industries Ltd

      Stock Reports

      Tue, 24 Jun 2014

      candidates to market could erode cash flows as these existing products face generic competition. Management recently settled with Wyeth (now part of Pfizer) for $1.6 billion over Teva’s at-risk launch--before legal clearance--of generic Protonix

    2. Pfizer: Pfine With Or Without AstraZeneca

      Headlines

      Mon, 23 Jun 2014

      decades has come through the company's numerous acquisitions, most notably Warner-Lambert in 2000, Pharmacia in 2003 and Wyeth in 2009. From the aforementioned key acquisitions or smaller separate acquisitions, Pfizer also includes assets of former

    3. ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush

      Headlines

      Fri, 30 May 2014

      string of big-ticket mergers. It bought Warner-Lambert in 2000 for $90 billion, Pharmacia in 2003 for $60 billion and Wyeth in 2009 for $68 billion. As a result of those mergers, Pfizer found itself saddled with some businesses it didn’t want

    4. New Morningstar Analyst Report for Pfizer Inc

      Stock Reports

      Wed, 28 May 2014

      statements. Pfizer is the world's largest pharmaceutical firm, with annual sales over $50 billion. Following the acquisition of Wyeth , prescription drugs now account for close to 90% of sales. Top sellers include cholesterol-lowering Lipitor, Celebrex

    5. New Morningstar Analyst Report for Pfizer Inc

      Stock Reports

      Wed, 28 May 2014

      faces significant integration risks with Wyeth . Flight of intellectual talent or failure ..... Cost-cutting efforts associated with the Wyeth merger could exceed our expectations ..... 22.5 billion in debt to finance the Wyeth acquisition, we believe its strong cash

    6. New Morningstar Analyst Report for Zoetis Inc

      Stock Reports

      Mon, 31 Mar 2014

      over the next five years. Zoetis has recently seen margin improvement due to synergies from the acquisitions of Fort Dodge ( Wyeth ) and Alpharma (King Pharma) and from Pfizer's companywide cost-reduction program. Management expects continued margin

    7. New Morningstar Analyst Report for Zoetis Inc

      Stock Reports

      Mon, 31 Mar 2014

      over the next five years. Zoetis has recently seen margin improvement due to synergies from the acquisitions of Fort Dodge ( Wyeth ) and Alpharma (King Pharma) and from Pfizer's companywide cost-reduction program. Management expects continued margin

    8. New Morningstar Analyst Report for ViroPharma, Inc.

      Stock Reports

      Mon, 11 Nov 2013

      question after the drug failed to reduce the rate of CMV disease for transplant patients in a Phase III trial.ViroPharma and Wyeth (now a part of Pfizer) broke off their partnership for the development of a hepatitis C drug after a Phase II trial revealed

    9. Mead Johnson Lowering Prices on Some China Products by 7%-15%; Maintaining Fair Value Estimate

      Commentary

      Wed, 10 Jul 2013

      China by 7%-15%, echoing changes made by competitors Danone BN (decreasing prices by 5%-20%), Nestle NESN (its Wyeth unit, acquired from Pfizer PFE , is lowering prices by 6%-20%), Abbott Laboratories ABT (4%-12%), and local competitors

    « Prev12345Next »
    Content Partners